These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 25616822)

  • 1. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial.
    Tepe G; Schnorr B; Albrecht T; Brechtel K; Claussen CD; Scheller B; Speck U; Zeller T
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):102-8. PubMed ID: 25616822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
    Scheinert D; Duda S; Zeller T; Krankenberg H; Ricke J; Bosiers M; Tepe G; Naisbitt S; Rosenfield K
    JACC Cardiovasc Interv; 2014 Jan; 7(1):10-9. PubMed ID: 24456716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study.
    Tepe G; Zeller T; Schnorr B; Claussen CD; Beschorner U; Brechtel K; Scheller B; Speck U
    J Endovasc Ther; 2013 Dec; 20(6):792-800. PubMed ID: 24325695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).
    Liistro F; Grotti S; Porto I; Angioli P; Ricci L; Ducci K; Falsini G; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1295-302. PubMed ID: 24239203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Arteries: Role of Paclitaxel Dose and Bioavailability.
    Katsanos K; Spiliopoulos S; Paraskevopoulos I; Diamantopoulos A; Karnabatidis D
    J Endovasc Ther; 2016 Apr; 23(2):356-70. PubMed ID: 26823485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial.
    Siablis D; Kitrou PM; Spiliopoulos S; Katsanos K; Karnabatidis D
    JACC Cardiovasc Interv; 2014 Sep; 7(9):1048-56. PubMed ID: 25234679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acotec Drug-Coated Balloon Catheter: Randomized, Multicenter, Controlled Clinical Study in Femoropopliteal Arteries: Evidence From the AcoArt I Trial.
    Jia X; Zhang J; Zhuang B; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1941-9. PubMed ID: 27659572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study.
    Liistro F; Angioli P; Porto I; Ricci L; Ducci K; Grotti S; Falsini G; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    J Endovasc Ther; 2014 Feb; 21(1):1-8. PubMed ID: 24502477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difference in one-year late lumen loss between high- and low-dose paclitaxel-coated balloons for femoropopliteal disease.
    Kodama K; Soga Y; Tomoi Y; Sakai N; Imada K; Katsuki T; Tabata H; Ando K; Nakagawa Y
    Heart Vessels; 2024 Jul; 39(7):582-588. PubMed ID: 38363331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of drug-coated balloon angioplasty versus uncoated balloon angioplasty in treatment of total occlusions with severe femoropopliteal lesions: An additional analysis from the AcoArt I study.
    Sun G; Liu J; Jia S; Zhang J; Zhuang B; Jia X; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W;
    Vascular; 2021 Jun; 29(3):340-349. PubMed ID: 32903168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
    J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
    [No Abstract]   [Full Text] [Related]  

  • 12. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
    Stabile E; Gerardi D; Magliulo F; Zhelev D; Chervenkoff V; Taeymans K; Kotasov D; Goverde P; Giugliano G; Trimarco B; Esposito G
    J Endovasc Ther; 2019 Feb; 26(1):26-30. PubMed ID: 30760132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
    Brodmann M; Keirse K; Scheinert D; Spak L; Jaff MR; Schmahl R; Li P; Zeller T;
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2113-2123. PubMed ID: 29050631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
    Teichgräber U; Aschenbach R; Scheinert D; Zeller T; Brechtel K; Thieme M; Blessing E; Treitl M; Lichtenberg M; von Flotow P; Vogel B; Werk M; Riambau V; Wienke A; Lehmann T; Sixt S
    Trials; 2016 Oct; 17(1):528. PubMed ID: 27793175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
    Micari A; Nerla R; Vadalà G; Castriota F; Grattoni C; Liso A; Russo P; Pantaleo P; Roscitano G; Cremonesi A
    JACC Cardiovasc Interv; 2017 Apr; 10(7):728-734. PubMed ID: 28385412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-coated balloons for failing peripheral bypass grafts: the BYPACS study.
    Kitrou P; Parthipun A; Diamantopoulos A; Padayachee S; Karunanithy N; Ahmed I; Zayed H; Katsanos K
    J Cardiovasc Surg (Torino); 2014 Apr; 55(2):217-24. PubMed ID: 24670829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty in patients with femoropopliteal arterial occlusive disease.
    Jongsma H; Bekken JA; de Vries JP; Verhagen HJ; Fioole B
    J Vasc Surg; 2016 Nov; 64(5):1503-1514. PubMed ID: 27478005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study.
    Reijnen MMPJ; van Wijck I; Zeller T; Micari A; Veroux P; Keirse K; Lee SW; Li P; Voulgaraki D; Holewijn S
    J Endovasc Ther; 2019 Jun; 26(3):305-315. PubMed ID: 30931726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The Chronic Total Occlusion Cohort in the IN.PACT Global Study.
    Tepe G; Micari A; Keirse K; Zeller T; Scheinert D; Li P; Schmahl R; Jaff MR;
    JACC Cardiovasc Interv; 2019 Mar; 12(5):484-493. PubMed ID: 30846089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
    Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.